JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 12 July 2006. doi:10.1136/jcp.2006.038752
Journal of Clinical Pathology 2007;60:167-172
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.038752v1
60/2/167    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Galen, J. C
Right arrow Articles by Meijer, C. J L M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Galen, J. C
Right arrow Articles by Meijer, C. J L M

ORIGINAL ARTICLE

Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL

Joost C van Galen1,*, Jettie J F Muris1,*, Joost J Oudejans1, Wim Vos1, Cindy P E Giroth1, Gert J Ossenkoppele2, Arie P Otte3, Frank M Raaphorst1,4, Chris J L M Meijer1

1 Departments of Pathology, VU Medical Center, Amsterdam, The Netherlands
2 Departments of Haematology, VU Medical Center, Amsterdam, The Netherlands
3 Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
4 Crucell Holland BV,Leiden, The Netherlands

Correspondence to:
Dr J J Oudejans
Department of Clinical Pathology, VU Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands; jj.oudejans{at}vumc.nl Background: : Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is highly variable and poorly predictable. Microarray studies showed that patients with DLBCL with a germinal centre B cell-like (GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. The BMI1 proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL, associated with a poor prognosis.

Objectives: : (1) To investigate, in primary nodal DLBCL, the expression of BMI1 and its association with clinical outcome and DLBCL signature; (2) to look for an association between BMI1 expression and the expression of its putative downstream targets p14ARF and p16INK4a.

Results: : BMI1 expression was found to be associated with poor clinical outcome, but not clearly with an ABC-like phenotype of DLBCL. Expression of BMI1 was frequently, but not always, related to low levels of expression of p14ARF and p16INK4a.

Conclusion: : Expression of BMI1 is associated with an unfavourable clinical outcome of primary nodal DLBCL.

Abbreviations: ABC, activated B cell; DLBCL, diffuse large B cell lymphomas; GCB, germinal centre B cells






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.